...
首页> 外文期刊>BMC Complementary and Alternative Medicine >All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy
【24h】

All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy

机译:全反式维甲酸诱导分化并使对乳腺癌具有放射敏感性的乳腺癌细胞敏感

获取原文

摘要

Background Radiotherapy is of critical importance in the treatment of breast cancer. However, not all patients derive therapeutic benefit and some breast cancers are resistant to the treatment, and are thus evidenced with prospective distant metastatic spread and local recurrence. In this study, we investigated the potential therapeutic effects of all-trans retinoic acid (ATRA) on radiation-resistant breast cancer cells and the associated invasiveness. Methods The MCF7/C6 cells with gained radiation resistance after a long term treatment with fractionated ionizing radiation were derived from human breast cancer MCF7 cell line, and are enriched with cells expressing putative breast cancer stem cell biomarker CD44+/CD24-/low/ALDH+. The enhanced invasiveness and the acquired resistances to chemotherapeutic treatments of MCF7/C6 cells were measured, and potential effects of all-trans retinoic acid (ATRA) on the induction of differentiation, invasion and migration, and on the sensitivities to chemotherapies in MCF7/C6 cells were investigated. Results MCF7/C6 cells are with enrichment of cancer stem-cell like cells with positive staining of CD44+/CD24-/low, OCT3/4 and NANOG. MCF7/C6 cells showed an increased tumoregensis potential and enhanced aggressiveness of invasion and migration. Treatment with ATRA induces the differentiation in MCF7/C6 cells, resulting in reduced invasiveness and migration, and increased sensitivity to Epirubincin treatment. Conclusion Our study suggests a potential clinic impact for ATRA as a chemotherapeutic agent for treatment of therapy-resistant breast cancer especially for the metastatic lesions. The study also provides a rationale for ATRA as a sensitizer of Epirubincin, a first-line treatment option for breast cancer patients.
机译:背景技术放射疗法在乳腺癌的治疗中至关重要。但是,并非所有患者都能获得治疗益处,并且某些乳腺癌对治疗有抵抗力,因此有前瞻性远处转移扩散和局部复发的证据。在这项研究中,我们调查了全反式视黄酸(ATRA)对抗辐射乳腺癌细胞及其相关侵袭性的潜在治疗作用。方法长期分次电离辐射治疗后获得抗辐射能力的MCF7 / C6细胞来源于人乳腺癌MCF7细胞系,并富含表达乳腺癌干细胞生物标志物CD44 + 的细胞/ CD24 -/ low / ALDH + 。测量了MCF7 / C6细胞的增强的侵袭性和获得的对化学疗法的抗性,以及全反式维甲酸(ATRA)对诱导分化,侵袭和迁移以及对MCF7 / C6的化学敏感性的潜在影响。细胞进行了调查。结果MCF7 / C6细胞富含癌干细胞样细胞,CD44 + / CD24 -/ low ,OCT3 / 4和NANOG呈阳性。 MCF7 / C6细胞显示出增加的egomaegensis潜力和增强的侵略性和迁移侵略性。 ATRA治疗可诱导MCF7 / C6细胞分化,从而减少侵袭性和迁移,并提高对表柔比星治疗的敏感性。结论我们的研究表明,ATRA作为化学治疗剂可治疗耐药性乳腺癌,尤其是转移性病变,可能对临床产生影响。该研究还为ATRA作为表柔比星的敏化剂提供了理论依据,这是乳腺癌患者的一线治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号